Page 8 - News VLU 05 JUN 2024
P. 8

Vein & Lymphatic University
                                                    VLU voices

       RESEARCH CORNER.          VLU is excited to announce a new initiative focusing on a
                                 new research article with cutting edge new ideas that can
                                 change clinical practice!
      Beyond the Bandage: Empowering Patients

      with Effective Lymphedema Management



      Viren S Sehgal, Brandon Eric Ruggeberg, Michael James
      Article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10931544/

        The study shines a light on the impor-  healthcare savings without compromising
       tance  of  effectively  managing  lymphe-  patient care. Overall, the insights from
       dema, by comparing the effectiveness of   this  study  offer  promising  directions  for
       intermittent pneumatic compression (IPC)   optimizing lymphedema maintenance the-
       compared with the main therapy for com-  rapy, aiming to strike a balance between
       plex decongestive therapy (CDT), manual   treatment  efficacy,  patient  comfort,  and
       lymphatic drainage (MLD).  Both MLD and   healthcare resource utilization.
                            1
       IPC were performed in extremities suffe-
       ring from lymphedema in two-day inter-  1 .Mendoza  E, Amsler  F.  Effectiveness  of
       vals,  then  therapies  were  quantified  with   manual lymphatic drainage and intermittent
       volume  measurement  of  the  limb  and  a   pneumatic compression in lymphedema
       questionnaire for   subjective symptoms.   maintenance therapy. Vasa. 2023;52(6):423-
       This study found no significant difference   431. doi:10.1024/0301-1526/a001090
       between  either  therapy  in  the  effective-  2 .Schara M, Zeng M, Jumet B, Preston DJ.
       ness for CDT, both for volume measure-  A low-cost wearable device for portable se-
       ment or subjective symptoms. Concluding   quential compression therapy.  Front Robot
       that IPC is comparable, and not inferior, to   AI. 2022;9:1012862. Published 2022 Nov
       the primary therapy for lymphedema. Fur-  14. doi:10.3389/frobt.2022.1012862
       thermore, IPC care is more cost-effective
       than other therapies.  A shift towards more
                       2
       frequent  IPC  use,  with  fewer  MLD  ses-
       sions  annually,  could  lead  to  substantial


                                        <












       8            veinuniversity.org
   3   4   5   6   7   8   9